Clinical Trial

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Study acronym: DanNORMS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
Trial Details
NCT Number NCT04688788
Lead Sponsor Rigshospitalet, Denmark
Collaborators: Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital, Herlev Hospital, Hillerod Hospital, Denmark, Kolding Sygehus, Gødstrup Hospital, Hvidovre University Hospital, Hospital of South West Jutland, Esbjerg, Denmark, University of Copenhagen, GCP-unit at Aarhus University Hospital, Aarhus, Denmark, Hospital of Southern Jutland, Sønderborg, Denmark, Hospital of Central Denmark Region, Viborg, Denmark, Danske Regioner, Hospital of Southern Jutland, Aabenraa, Denmark, Sanquin Research & Blood Bank Divisions
Conditions Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Enrollment 600 participants
Start Date 2021-04-28
Primary Completion 2026-06-10 (estimated)
Study Completion 2029-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-10